<Record>
<Term>Zolasartan</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Angiotensin II Receptor Antagonist</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Adjuvant/Cardiovascular Agent/Antihypertensive Agent/Angiotensin II Receptor Antagonist/Zolasartan</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Zolasartan</BroaderTerm>
<BroaderTerm>Cardiovascular Agent</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Adjuvant</BroaderTerm>
<BroaderTerm>Angiotensin II Receptor Antagonist</BroaderTerm>
<BroaderTerm>Antihypertensive Agent</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>GR 117289</Synonym>
<Synonym>ZOLASARTAN</Synonym>
<Synonym>Zolasartan</Synonym>
<Description>A nonpeptide angiotensin II receptor antagonist with antihypertensive activity. Zolasartan selectively competes with angiotensin II for the binding of the angiotensin II (AT1) receptor subtype 1 in vascular smooth muscle, thereby blocking angiotensin II-mediated vasoconstriction resulting in vascular dilatation. In addition, the antagonistic effect on AT1 in the adrenal gland, prevents angiotensin II-induced stimulation of aldosterone synthesis and secretion by the adrenal cortex. This blocks the effects of aldosterone leading to an increase in sodium excretion and water and eventually a reduction in plasma volume and blood pressure.</Description>
<Source>NCI Thesaurus</Source>
</Record>
